<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article147</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CYTO-PV" style="display:block; margin-bottom:10px;">CYTO-PV Original</a></li>
<h2><strong>CYTO-PV</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Hematocrit Targeting in Polycythemia Vera". The New England Journal of Medicine. 2012.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with JAK2-positive polycythemia vera, does maintaining a hematocrit below 45% reduce the risk of cardiovascular death and major thrombosis compared to a higher hematocrit target?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with JAK2-positive polycythemia vera, maintaining a hematocrit target below 45% results in a significantly lower rate of cardiovascular death and major thrombosis compared to a target of 45 to 50%.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Based on this study's findings, it is recommended that the hematocrit be maintained below 45% in patients with polycythemia vera to reduce the risk of cardiovascular death and major thrombotic events.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, prospective, randomized, open-label clinical trial<br/>
- N=365 adults with JAK2-positive polycythemia vera<br/>
- Low-hematocrit group (n=182) with a hematocrit target of less than 45%<br/>
- High-hematocrit group (n=183) with a hematocrit target of 45 to 50%<br/>
- Median follow-up: 31 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Adults with JAK2-positive polycythemia vera, per WHO 2008 diagnostic criteria<br/>
- Exclusion Criteria: Significant liver or renal disease, substance/alcohol abuse, pregnancy, life-threatening conditions, history of adverse reactions to hydroxyurea<br/>
- Baseline demographics were well-balanced between groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were assigned to receive phlebotomy, hydroxyurea, or both for targeted hematocrit management.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome: Time until death from cardiovascular causes or a major thrombotic event<br/>
- Secondary outcome: Total rate of cardiovascular events<br/>
- Additional outcomes: Incidence of cancer, progression to myelofibrosis, myelodysplasia, leukemic transformation, and hemorrhage<br/>
- Primary outcome observed in 2.7% of the low-hematocrit group vs. 9.8% of the high-hematocrit group (hazard ratio 3.91; P=0.007)<br/>
- No significant difference in adverse events between groups<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Although halted before the planned endpoint due to recruitment challenges, the study results provided unexpected evidence for the benefit of intensive hematocrit reduction.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by the Italian Medicines Agency (AIFA) and Associazione Italiana per la Ricerca sul Cancroâ€“Gruppo Italiano Malattie Mieloproliferative (AIRC-GIMEMA).<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full results published in The New England Journal of Medicine, December 8, 2012.  <br/>
- Disclosure forms and additional supporting materials available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
